Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 3,177 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 3,177 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $47.92, for a total transaction of $152,241.84. Following the completion of the transaction, the chief operating officer now directly owns 29,588 shares in the company, valued at approximately $1,417,856.96. The trade was a 9.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Peter Radovich also recently made the following trade(s):

• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total value of $85,554.36.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock traded up $0.95 on Monday, reaching $48.48. 1,319,360 shares of the company traded hands, compared to its average volume of 540,941. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm has a market capitalization of $2.33 billion, a PE ratio of -24.00 and a beta of 0.98. The company has a 50 day moving average of $43.76 and a 200 day moving average of $41.61. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $49.40.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. During the same period last year, the business posted ($0.57) earnings per share. The business’s revenue for the quarter was up 89.4% on a year-over-year basis. Equities analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on MIRM. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Citigroup upped their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners raised their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, HC Wainwright restated a “buy” rating and set a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $57.10.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Golden State Equity Partners raised its position in shares of Mirum Pharmaceuticals by 1,390.8% in the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company’s stock valued at $801,000 after purchasing an additional 18,080 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Mirum Pharmaceuticals by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock valued at $421,000 after buying an additional 1,003 shares in the last quarter. R Squared Ltd bought a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $69,000. Secure Asset Management LLC lifted its position in shares of Mirum Pharmaceuticals by 9.3% during the fourth quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock worth $1,651,000 after acquiring an additional 3,406 shares in the last quarter. Finally, Avanza Fonder AB bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth $189,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.